A new report has projected the market to exceed $310m by 2027.
Canxchange is introducing more transparency, liquidity and efficiency to the growing cannabis market through its new platform.
Oxford Cannabinoid Technologies Holdings has begun 2022 with a positive start and has announced a new date for the start of its Phase I trial.
The company has announced a new parent name and a profitable second fiscal quarter, with ongoing progress across the EU.
The new Research and Markets report estimates the market will grow at a CAGR of 19.6 per cent.
Canxchange explores trust and credibility in the cannabis industry.
The GCI Virtual Summit explored key factors that investors look for in cannabis businesses when analysing investment opportunities.
2021 has seen the introduction of the company’s proprietary technology as well as milestone employee growth.
Pharma titan Pfizer is to acquire Arena Pharmaceuticals which has a pipeline in cannabinoid therapeutics.
2021 has been a good year for the cannabis industry, says the new Brightfield Group report.
